Synaptogenix Crescita futura
Future criteri di controllo 0/6
Synaptogenix's earnings are forecast to decline at 37.6% per annum. EPS is expected to decline by 0.5% per annum.
Informazioni chiave
-37.6%
Tasso di crescita degli utili
-0.5%
Tasso di crescita dell'EPS
Biotechs crescita degli utili | 27.1% |
Tasso di crescita dei ricavi | n/a |
Rendimento futuro del capitale proprio | n/a |
Copertura analitica | Low |
Ultimo aggiornamento | 11 Jul 2024 |
Aggiornamenti recenti sulla crescita futura
Nessun aggiornamento
Recent updates
We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth
Sep 20Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth
May 10Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
Nov 17Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans
Oct 05Synaptogenix: The Next Big Thing In Alzheimer's
Jun 16Synaptogenix provides update on phase 2b Alzheimer's disease trial
Jun 09We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate
Jun 09Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
12/31/2026 | N/A | -21 | N/A | N/A | 1 |
12/31/2025 | N/A | -13 | N/A | N/A | 1 |
12/31/2024 | N/A | -8 | N/A | N/A | 1 |
6/30/2024 | N/A | -3 | -5 | -5 | N/A |
3/31/2024 | N/A | -12 | -5 | -5 | N/A |
12/31/2023 | N/A | -14 | -5 | -5 | N/A |
9/30/2023 | N/A | -8 | -7 | -7 | N/A |
6/30/2023 | N/A | -11 | -8 | -8 | N/A |
3/31/2023 | N/A | -4 | -9 | -9 | N/A |
12/31/2022 | N/A | -6 | -11 | -11 | N/A |
9/30/2022 | N/A | -14 | -10 | -10 | N/A |
6/30/2022 | N/A | -14 | -9 | -9 | N/A |
3/31/2022 | N/A | -13 | -9 | -9 | N/A |
12/31/2021 | N/A | -13 | -9 | -9 | N/A |
9/30/2021 | N/A | -14 | -8 | -8 | N/A |
6/30/2021 | N/A | -15 | -10 | -10 | N/A |
3/31/2021 | N/A | -16 | -10 | -10 | N/A |
12/31/2020 | N/A | -15 | -8 | -8 | N/A |
9/30/2020 | N/A | -12 | -8 | -8 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: SNPX is forecast to remain unprofitable over the next 3 years.
Guadagni vs Mercato: SNPX is forecast to remain unprofitable over the next 3 years.
Guadagni ad alta crescita: SNPX is forecast to remain unprofitable over the next 3 years.
Ricavi vs Mercato: Insufficient data to determine if SNPX's revenue is forecast to grow faster than the US market.
Ricavi ad alta crescita: SNPX is forecast to have no revenue next year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if SNPX's Return on Equity is forecast to be high in 3 years time